Legal Representation
Attorney
Andrew Fisher
USPTO Deadlines
Application History
17 eventsDate | Code | Type | Description |
---|---|---|---|
Nov 5, 2003 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
Apr 7, 2003 | EX4G | S | SOU EXTENSION 4 GRANTED |
Feb 4, 2003 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Feb 4, 2003 | EXT4 | S | SOU EXTENSION 4 FILED |
Oct 2, 2002 | EX3G | S | SOU EXTENSION 3 GRANTED |
Sep 5, 2002 | I | PAPER RECEIVED | |
Sep 4, 2002 | EXT3 | S | SOU EXTENSION 3 FILED |
Mar 22, 2002 | EX2G | S | SOU EXTENSION 2 GRANTED |
Mar 6, 2002 | I | PAPER RECEIVED | |
Mar 6, 2002 | EXT2 | S | SOU EXTENSION 2 FILED |
Sep 19, 2001 | EX1G | S | SOU EXTENSION 1 GRANTED |
Sep 5, 2001 | EXT1 | S | SOU EXTENSION 1 FILED |
Mar 6, 2001 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
Dec 12, 2000 | PUBO | A | PUBLISHED FOR OPPOSITION |
Nov 10, 2000 | NPUB | O | NOTICE OF PUBLICATION |
Jul 25, 2000 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jul 18, 2000 | DOCK | D | ASSIGNED TO EXAMINER |
Detailed Classifications
Class 005
pharmaceutical preparation used in the treatment of congestive heart failure, stroke and other cardiovascular diseases
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
UNIQUE PEG
Classification
International Classes
005